



# GANNET53

## EUROPEAN PROJECT

Kick-Off Meeting Agenda - 12th Oct 2013  
Sheraton Hotel, Frankfurt Airport

---

<b>9:00</b>	Welcome	<i>N. Concin, C. Marth / IMU</i>
<b>9:15</b>	Project overview: Management	<i>N. Concin / IMU</i>
<b>9:30</b>	Introduction of partners	<i>All</i>
<b>10:00</b>	Stabilised mutant p53 protein: a novel, rational & potent druggable target in cancer treatment	<i>U. Moll / UMG-GOE</i>
<b>10:35</b>	Why in ovarian cancer? Rationale for a stratified treatment approach	<i>A. Zeimet / IMU</i>
<b>11:00</b>	<b>COFFEE BREAK</b>	
<b>11:30</b>	Targeting HSP90 with Ganetespib - an overview	<i>V. Vukovich/ Synta Pharmaceuticals</i>
<b>12:00</b>	Project management	<i>A. Flanderfer / OncoLab</i>
<b>12:30</b>	<b>LUNCH</b>	
<b>13:30</b>	WP2 - Preparations for clinical trials	<i>R. Berger / IMU</i>
<b>14:00</b>	WP3 - Phase I dose escalation / de-escalation trial	<i>I. Ray-Coquard / CLB</i>
<b>14:40</b>	WP4 – Randomised, two arm Phase II trial	<i>I. Vergote / KU Leuven</i>
<b>15:20</b>	<b>COFFEE BREAK</b>	
<b>15:50</b>	WP5 - Central histopathological review, biobanking & data repository	<i>I. Braicu / CHARITE</i>
<b>16:30</b>	WP6 - Companion diagnostics	<i>R. Zeillinger / OncoLab</i>
<b>17:10</b>	Discussion	<i>All</i>
<b>18:10</b>	Resumee and closing remarks of the national trial group leaders	<i>E. Pujade-Lauraine / GINECO, J. Sehouli / NOGGO S. Mahner / G-AGO, C. Marth / A-AGO</i>
<b>18:30</b>	<b>CLOSURE</b>	<i>N. Concin / IMU</i>

